Collegium Pharmaceutical, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 276.87M | 463.93M | 566.77M | 631.45M | 780.57M | 23.6% | |
| Cost of Revenue | (126.25M) | (254.44M) | (240.60M) | (254.10M) | (317.31M) | 24.9% | |
Gross Profit | 150.62M | 209.49M | 326.17M | 377.34M | 463.26M | 22.8% | |
| Operating Expenses | |||||||
| Research & Development | (9.45M) | (3.98M) | — | — | — | — | |
| Selling, General & Administrative | (118.96M) | (172.19M) | (159.21M) | (182.98M) | (276.17M) | 50.9% | |
| Depreciation & Amortization | (68.92M) | (138.94M) | (149.26M) | (169.16M) | (226.07M) | 33.6% | |
Operating Income (EBIT) | 17.63M | 33.32M | 166.96M | 169.90M | 187.08M | 10.1% | |
| Non-Operating Items | |||||||
| Interest Income | 12.00K | 1.05M | 15.62M | 13.98M | 11.29M | -19.2% | |
| Interest Expense | (21.01M) | (63.21M) | (83.34M) | (73.97M) | (82.31M) | 11.3% | |
| Other Income/Expenses (Net) | -21.00M | -62.17M | -91.23M | -71.33M | -94.47M | 32.4% | |
Income Before Tax | -3.37M | -28.85M | 75.73M | 98.57M | 92.62M | -6.0% | |
| Income Tax Expense | (74.89M) | (3.85M) | (27.58M) | (29.38M) | (29.75M) | 1.3% | |
Net Income | 71.52M | -25.00M | 48.16M | 69.19M | 62.87M | -9.1% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $2 | $-1 | $2 | $2 | $2 | -7.5% | |
| Weighted Avg Shares Outstanding | 34.94M | 33.83M | 33.74M | 32.27M | 31.71M | -1.8% | |
| Weighted Avg Shares Outstanding (Diluted) | 41.05M | 33.83M | 41.79M | 40.42M | 39.70M | -1.8% | |
EBITDA | 86.56M | 173.31M | 308.33M | 341.70M | 401.00M | 17.4% |
Explore COLL
COLL in the Healthcare
Small Cap